Background
Methods
Study population and design
T0 visit
Monitoring period
T1 visit
The DuoBaby device
Randomization
Primary and secondary outcome
Sample size
Statistical analysis
Results
Characteristics of the study population
Cases | Controls | ||||
---|---|---|---|---|---|
n = 43b | n = 46b | pa | |||
Male gender (n; %) | 27 |
62.8
| 34 |
73.9
| 0.361 |
Age (months) (median, IQR) | 30 |
(20–60)
| 35 |
(18–52)
| 0.767 |
Older sibling (n; %) | 18 |
41.9
| 23 |
50.0
| 0.441 |
Younger sibling (n; %) | 4 |
9.3
| 8 |
17.4
| 0.356 |
Full breast-feeding (4 month) (n; %) | 33 |
76.7
| 32 |
69.6
| 0.482 |
Weaning (age in months) (mean; SD) | 5.6 |
1.0
| 5.4 |
1.5
| 0.136 |
Caucasian (n; %) | 32 |
74.4
| 36 |
78.3
| 0.670 |
Passive smoke (n; %) | 9 |
20.9
| 7 |
15.2
| 0.585 |
Cough outside cold (n; %) | 27 |
63
| 27 |
59
| 0.859 |
Sleep disorders (n; %) | 37 |
86
| 37 |
80
| 0.576 |
Emergency events (n; %) | 22 |
51
| 24 |
52
| 1.000 |
Hospitalization (n; %) | 6 |
14
| 9 |
20
| 0.576 |
Missed school-days (n; %) | 35 |
81
| 38 |
83
| 1.000 |
Responder (n, %) | |||||
Mother | 26 |
60
| 31 |
67
| 0.6729 |
Father | 6 |
14
| 7 |
15
| |
Both | 11 |
26
| 8 |
17
|
Patients’ evaluation of the nebulizer and of the nasal aspirator
Cases | Controls | ||||
---|---|---|---|---|---|
n = 43b | n = 46b | pa | |||
n |
%
| n |
%
| ||
Handling the nebulizer | |||||
Easy | 39 |
98
| 39 |
93
| 0.241 |
Difficult | 0 |
0
| 3 |
7
| |
Impossible | 1 |
3
| 0 |
0
| |
Assembly of the nebulizer | |||||
Easy | 37 |
95
| 38 |
90
| 0.677 |
Quick solved problems | 2 |
5
| 4 |
10
| |
Difficult | 0 |
0
| 0 |
0
| |
Child’s tolerance of nebulization | |||||
No problems | 23 |
58
| 25 |
60
| 0.527 |
Some problems | 17 |
43
| 15 |
36
| |
Inhalation impossible | 0 |
0
| 2 |
5
| |
Cleaning of the nebulizer | |||||
Easy | 35 |
90
| 40 |
95
| 0.670 |
Quickly solved problems | 3 |
8
| 1 |
2
| |
Difficult | 1 |
3
| 1 |
2
| |
Nebulization improved symptoms | |||||
Yes | 18 |
53
| 17 |
46
| 0.726 |
Partially | 13 |
38
| 17 |
46
| |
No | 3 |
9
| 3 |
8
| |
Nebulization was beneficial | |||||
Yes | 30 |
81
| 27 |
69
| 0.035 |
Rather yes | 1 |
3
| 7 |
18
| |
Rather no | 3 |
8
| 5 |
13
| |
No | 3 |
8
| 0 |
0
| |
Future use of nebulizer wished | |||||
Yes | 28 |
70
| 29 |
69
| 0.405 |
Rather yes | 5 |
13
| 2 |
5
| |
Rather no | 6 |
15
| 7 |
17
| |
No | 1 |
3
| 4 |
10
| |
Nebulizer use recommendable to others | |||||
Yes | 31 |
77.5
| 34 |
79
| 0.386 |
Rather yes | 5 |
12.5
| 4 |
9
| |
Rather no | 2 |
5.0
| 5 |
12
| |
No | 2 |
5.0
| 0 |
0
|
na | % | |
---|---|---|
Assembly of DuoBaby Aspirator | ||
No problems | 37 |
93
|
Quickly solved problems | 1 |
3
|
Difficult | 2 |
5
|
Aspirator cleaning | ||
No problems | 33 |
83
|
Quickly solved problems | 5 |
12
|
Difficult | 2 |
5
|
Removal of nasal secretum | ||
Complete | 7 |
19
|
Partial | 20 |
54
|
Insufficient | 10 |
27
|
Aspiration improved symptoms | ||
Yes | 6 |
17
|
Partially | 16 |
46
|
No | 13 |
37
|
Aspiration improved sleep | ||
Yes | 6 |
17
|
Rather yes | 14 |
40
|
Rather no | 7 |
20
|
No | 8 |
23
|
Aspiration improved eating | ||
Yes | 6 |
17
|
Rather yes | 12 |
33
|
Rather no | 8 |
22
|
No | 10 |
28
|
Aspiration improved wellness | ||
Yes | 10 |
28
|
Rather yes | 10 |
28
|
Rather no | 6 |
17
|
No | 10 |
28
|
Aspiration was beneficial | ||
Yes | 13 |
34
|
Rather yes | 5 |
13
|
Rather no | 8 |
21
|
No | 12 |
32
|
Frequency of respiratory symptoms and of salbutamol inhalation
Cases n = 43 | Controls n = 46 | pb | |||
---|---|---|---|---|---|
Mediana | IQR | Mediana | IQR | ||
Nasal symptoms in the last 24 h | 25.0 |
(14.5–43.6)
| 46.4 | (27.4–58.4) |
0.004
|
Runny nose | 21.0 |
(10.6–37.3)
| 39.5 |
(22.5–48.3)
|
0.021
|
Stuffy nose | 15.3 |
(6.4–32.1)
| 24.0 |
(7.5–44.6)
| 0.160 |
Mucus | 14.4 |
(3.4–34)
| 21.1 |
(7.1–38.3)
| 0.289 |
Crusts | 1.5 |
(0–15.6)
| 6.7 |
(0–20.1)
| 0.485 |
Bronchial symptoms in the last 24 h | 21.8 |
(14.5–37.3)
| 32.8 | (16.8–50.3) |
0.022
|
Dry cough | 12.7 |
(3.5–25.8)
| 17.8 |
(5.8–32.1)
| 0.229 |
Productive cough | 14.7 |
(6.5–18.9)
| 20.3 |
(9.3–37.7)
|
0.033
|
Wheezing | 3.6 |
(0–10.3)
| 2.6 |
(0–10.8)
| 1.000 |
Difficult breathing | 0.0 |
(0–3.3)
| 0.0 |
(0–3)
| 0.836 |
Fever | 3.1 |
(0.8–5.3)
| 4.2 |
(1.6–6.9)
| 0.152 |
Sore throat | 1.4 |
(0–3.2)
| 0.7 |
(0–4.3)
| 0.800 |
Earache | 0.0 |
(0–1.2)
| 0.0 |
(0–2.2)
| 0.105 |
Hoarseness | 0.8 |
(0–4.1)
| 0.4 |
(0–1.8)
| 0.342 |
Sleep disorders | 6.0 |
(2.2–12)
| 6.3 |
(2.4–14.9)
| 0.690 |
Loss of appetite | 3.2 |
(0–8.2)
| 3.1 |
(0.9–6.7)
| 0.747 |
Anxiety / restlessness | 2.0 |
(0–4.7)
| 1.0 |
(0–6.6)
| 0.537 |
Cases | Controls | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
control therapy | no control therapy | control therapy | no control therapy | |||||||
n = 6 | n = 37 | n = 10 | n = 36 | pb | pc | |||||
Mediana | IQR | Mediana | IQR | Mediana | IQR | Mediana | IQR | |||
Nasal symptoms in the last 24 h | 40.4 |
(30.8–74.9)
| 23.2 |
(13.3–41.2)
| 54.2 |
(49.3–57.9)
| 39.7 |
(24.9–58.5)
| 0.020 | 0.011 |
Bronchial symptoms in the last 24 h | 40.6 |
(39.6–56.1)
| 20.8 |
(12.5–32.3)
| 34.6 | (27.8–50.4) | 29.7 | (15–50.1) | 0.035 | 0.031 |